Subcutaneous, long-acting, rFVIIa derivative
:Haemostatic agent
:Phase 1
Novo Nordisk is developing a glyco-PEGylated derivative of rFVIIa for subcutaneous administration intended for prophylactic use in haemophilia patients with inhibitors (NN7129).
- Company announcements
- Interim financial report for the period 1 January 2010 to 30 June 2010 (05 Aug 2010)
- Financial statement for 2008 (29 Jan 2009)
- Major shareholder notification (07 Nov 2008)
- Read more company announcements
- Press releases
- Novo Nordisk partners with international scientific community for Victoza® cardiovascular outcomes trial (06 May 2010)
- Minister presents scholarships to young research talents (21 Jan 2010)
- Novo Nordisk licenses IL-21 mAb and patent rights to IL-21 antibodies from ZymoGenetics (08 Dec 2009)
- Read more press releases
- Scientific abstracts
No scientific abstracts matching the search criteria
